TB-500 Legal and Patent Challenges: Regulatory Status, FDA Position, and Compounding Access
Key numbers
- 2 mg to 15 mgVial sizes in which unapproved 'research use only' powder is sold onlineSource: fda.gov, as cited Nov 7, 2026
- 3 mg/mLConcentration of the lyophilized powder proposed in the nomination FDA reviewed; no human dosing study existsSource: fda.gov, as cited Nov 7, 2026
- 5 mg/5 mgStrength of an unapproved BPC-157 and TB-500 blend linked to skin darkening in one reported caseSource: fda.gov, as cited Nov 7, 2026
See the public record for TB-500
At a glance
- FDA approval / None, for any indication [1]
- What it is / Synthetic 7-amino-acid fragment of thymosin beta-4, about 889 g/mol [1]
- FDA bulks lists / On none of them, including category 1 [2][3][4]
- Safety-risk page / In the 'nominated but withdrawn' table, not the active category 2 table [8]
- Advisory committee / Voted on 23 July 2026 to recommend listing it; advice only [5][6]
- HHS draft policy / Names TB-500 acetate for injection; draft, non-binding [6][7]
- Human data / No study in which TB-500 was given to a person [1]
- Sport / WADA section S2.3, prohibited at all times [9][10]
What is TB-500's regulatory status in the United States?
TB-500 is not an FDA-approved drug. FDA's July 2026 review found no United States Pharmacopeia or National Formulary monograph for it, no FDA-approved drug containing it, no entry in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1]. 'TB-500' is a common name, not an official drug name, and FDA found several salts and derivatives, including different active moieties, sold under it [1].
To be used as a bulk substance by a state-licensed pharmacy or physician, a substance must comply with a USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's list of bulk substances that can be used in compounding [4]. TB-500 meets none of those three conditions: FDA found no monograph and no approved drug containing it [1], and it is not on the list [2].
TB-500 is a fragment of thymosin beta-4, not the protein itself
TB-500 is a synthetic 7-amino-acid fragment (residues 17 to 23, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, N-acetylated) of the 43-amino-acid protein thymosin beta-4, with a molecular weight of about 889 g/mol [1]. It is not full-length thymosin beta-4, and it is not thymosin alpha-1 [1]. It appears to have first been synthesized in 2003, and a veterinary preparation marketed to boost performance in horses and greyhounds appeared in 2011 [1]. It is sold online as a 'research use only' injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1].
Why FDA staff recommended against adding TB-500 to the list
FDA staff's July 2026 briefing document gave several reasons for proposing that neither TB-500 free base nor TB-500 acetate be added: the substance is not well characterized (inconsistent naming, no impurity, aggregate or endotoxin data), its historical use is unclear, there is no evidence of effectiveness for wound healing, the use FDA evaluated, there are no human data for TB-500 itself, an injectable peptide carries immunogenicity risk, and FDA-approved wound treatments already exist [1].
FDA found no study in which TB-500 was given to a person, and none of the three papers the nominator cited involved TB-500 in humans [1]. The same review found no in-vivo animal study of TB-500 for wound healing; in an in-vitro scratch-wound test, TB-500 at 50 micrograms per millilitre did not induce wound closure in fibroblast cultures, while a shorter metabolite, N-acetylated LKKTE, did show activity [1].
The safety file was thin as well. FDA found no human pharmacokinetic or pharmacodynamic data for TB-500 by any route, no nonclinical toxicity studies and no immunogenicity or aggregation studies, and its stated concern for an injectable is immunogenicity, potentially amplified by peptide aggregation and impurities [1]. An adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and FDA's food and supplement complaint system from January 1, 2004 to March 10, 2025 retrieved two cases about a blended TB-500 and BPC-157 product with no safety assessment [1].
FDA's review of BPC-157 describes a report involving a 40-year-old woman who used a 'research purposes only' product containing both BPC-157 and TB-500 (5 mg/5 mg), injected subcutaneously twice daily, and developed widespread skin hyperpigmentation and gum darkening within a week, which recurred when she re-tried the product two weeks later; because the product contained two peptides, FDA said it cannot tell whether either caused it [15].
Where TB-500 sits on FDA's compounding lists
TB-500 appears in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, and in none of the categories on the separate list for outsourcing facilities, updated March 21, 2025 [2][3][4]. The category 1 policy, under which FDA says it does not intend to take action against a compounder using a listed substance if the conditions are met, does not cover it [4]. FDA also found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
TB-500 does appear on FDA's page about bulk substances that may present significant safety risks, but in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them, not in the active category 2 table [8]. FDA's stated concerns on that page are that it 'has not identified any human exposure data' on drug products containing the fragment, that it lacks important safety information, and that injectable peptides may pose immunogenicity risk because of aggregation and peptide-related impurities; removal from category 2 was not a finding that it is safe [8].
Questions worth asking
What the July 2026 advisory committee vote does and does not do
The Pharmacy Compounding Advisory Committee took up TB-500 free base and TB-500 acetate on July 23, 2026, with wound healing as the use FDA evaluated, and voted in favor of adding it to the bulks list, against the staff recommendation [5][6]. Advisory committees make non-binding recommendations, which FDA generally follows but is not legally bound to follow [5]. TB-500 is not on the list, and adding it takes formal rulemaking [5][6].
The October 2026 HHS draft policy, explained
HHS filed a draft enforcement-discretion policy for compounding with certain peptides on October 28, 2026, Federal Register document 2026-22192, with publication scheduled for October 30, 2026 and comments due two weeks after publication [6]. It names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, and it covers TB-500 acetate given by subcutaneous or intramuscular injection [6][7]. Under the draft, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with the peptide if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, a manufacturer registered with FDA that provides a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [6][7].
The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue arises [6]. It is not an FDA approval and does not put TB-500 on any list [6]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [6].
Sport: WADA prohibits it at all times
WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3, growth factors and growth factor modulators; it is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [9]. It is on the 2026 List, in force since January 1, 2026, and stays on the 2027 List in the tracked-changes version dated August 26, 2026 [9][10]. Laboratories have worked on detection: WADA approved a 2013 project on TB-500 metabolite detection limits, and a 2012 paper synthesized and characterized the N-acetylated 17-23 fragment 'identified in TB-500, a product suspected to possess doping potential' and proposed a detection strategy for plasma and urine [1][16].
Do trials of thymosin beta-4 apply to TB-500?
They do not. The human trials in this field tested full-length thymosin beta-4, not the 7-amino-acid fragment: a phase 1 study of recombinant human thymosin beta-4 given intravenously to healthy volunteers, thymosin beta-4 eye drops for dry eye, and recombinant thymosin beta-4 after a heart attack [11][12][13][14]. In the 72-person dry-eye trial, neither primary endpoint showed a significant difference from placebo [12]. Results from these products do not establish that TB-500 is safe or effective.
Dosing and labeling
There is no approved prescribing information, no labeled indication and no approved dose for TB-500. The nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection, and there is no human dosing study [1].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is TB-500 FDA approved?
Can a compounding pharmacy make TB-500?
Did the FDA advisory committee approve TB-500?
Does the October 2026 HHS policy make TB-500 legal?
Is TB-500 banned in sport?
References
Show all 16 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6.
- Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758.
- U.S. Food and Drug Administration.
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8.